Renaissance Technologies’s Theriva Biologics TOVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,148
| Closed | -$24.5K | – | 3892 |
|
|
2024
Q2 | $24.5K | Buy |
4,148
+1,408
| +51% | +$8.32K | ﹤0.01% | 3365 |
|
|
2024
Q1 | $32K | Buy |
2,740
+372
| +16% | +$4.35K | ﹤0.01% | 3546 |
|
|
2023
Q4 | $25K | Buy |
2,368
+200
| +9% | +$2.11K | ﹤0.01% | 3563 |
|
|
2023
Q3 | $29K | Buy |
2,168
+620
| +40% | +$8.29K | ﹤0.01% | 3477 |
|
|
2023
Q2 | $39K | Buy |
1,548
+160
| +12% | +$4.03K | ﹤0.01% | 3657 |
|
|
2023
Q1 | $24K | Buy |
1,388
+88
| +7% | +$1.52K | ﹤0.01% | 3797 |
|
|
2022
Q4 | $15K | Buy |
1,300
+32
| +3% | +$369 | ﹤0.01% | 4009 |
|
|
2022
Q3 | $31K | Buy |
1,268
+392
| +45% | +$9.58K | ﹤0.01% | 3840 |
|
|
2022
Q2 | $47K | Buy |
876
+446
| +104% | +$23.9K | ﹤0.01% | 4004 |
|
|
2022
Q1 | $31K | Buy |
430
+348
| +424% | +$25.1K | ﹤0.01% | 3969 |
|
|
2021
Q4 | $6K | Buy |
+82
| New | +$6K | ﹤0.01% | 3859 |
|
|
2021
Q1 | – | Sell |
-4,951
| Closed | -$474K | – | 3706 |
|
|
2020
Q4 | $474K | Buy |
4,951
+1,512
| +44% | +$145K | ﹤0.01% | 2842 |
|
|
2020
Q3 | $408K | Sell |
3,439
-119
| -3% | -$14.1K | ﹤0.01% | 2891 |
|
|
2020
Q2 | $455K | Buy |
3,558
+803
| +29% | +$103K | ﹤0.01% | 2910 |
|
|
2020
Q1 | $221K | Buy |
2,755
+428
| +18% | +$34.3K | ﹤0.01% | 3078 |
|
|
2019
Q4 | $295K | Buy |
2,327
+321
| +16% | +$40.7K | ﹤0.01% | 3075 |
|
|
2019
Q3 | $228K | Buy |
2,006
+260
| +15% | +$29.6K | ﹤0.01% | 3110 |
|
|
2019
Q2 | $240K | Buy |
1,746
+139
| +9% | +$19.1K | ﹤0.01% | 3255 |
|
|
2019
Q1 | $273K | Buy |
1,607
+204
| +15% | +$34.7K | ﹤0.01% | 3123 |
|
|
2018
Q4 | $196K | Buy |
1,403
+1,222
| +675% | +$171K | ﹤0.01% | 3140 |
|
|
2018
Q3 | $118K | Buy |
+181
| New | +$118K | ﹤0.01% | 3229 |
|
|
2017
Q2 | – | Sell |
-3
| Closed | -$14K | – | 3363 |
|
|
2017
Q1 | $14K | Buy |
+3
| New | +$14K | ﹤0.01% | 3182 |
|